GSK: revenue of Seretide/Advair globally by region 2012-2018

This statistic depicts the global revenue of Seretide/Advair around the world from 2012 to 2018, by region. Seretide/Advair generated a revenue of 1.83 billion British pounds in 2016 in the United States alone. Advair is the brand name marketed in the U.S. and Canada but is known as Seretide in many other countries. This pharmaceutical product is used to treat asthma through a combination of a preventer inhaler and a symptom controller.

Revenue of GlaxoSmithKline's Seretide/Advair worldwide from 2012 to 2018, by region

Loading statistic...
You need to log in to download this statistic
Register for free
Already a member?
Log in
Show detailed source information?
Register for free
Already a member?
Log in
Source

Release date

March 2019

Region

Worldwide

Survey time period

2012 to 2018

Supplementary notes

This statistic was assembled from several editions of GSK's annual report.
* From 2015 on, all other countries except the United States and European countries are included in "rest of world".

Statista Accounts: Access All Statistics. Starting from $708 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.

Single Account
Your perfect start with Statista
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references

$59 / Month *

Corporate Account
Full access

Corporate solution including all features.

* All products require an annual contract.
   Prices do not include sales tax.

Statistics on "Pharmaceutical brands: Advair/Seretide (GlaxoSmithKline)"

Statista Accounts: Access All Statistics. Starting from $708 / Year
Learn more about how Statista can support your business.